Form 4: Amphastar Pharmaceuticals CFO William J. Peters Executes Stock Option and Sells Shares

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options and sold shares on July 31, 2024, according to a Form 4 filing with the SEC.

Summary

• On July 31, 2024, William J. Peters, the CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised employee stock options to acquire 10,282 shares of common stock at a price of $20.23 per share.
• Simultaneously, Peters sold 10,282 shares of common stock at $44.23 per share.
• Following these transactions, Peters directly owns 94,103 shares of Amphastar Pharmaceuticals common stock.
• Peters also directly owns 4,943 derivative securities in the form of employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of any fundamental change in the company's prospects. The CFO exercising options is a positive, but the subsequent sale is a neutral event given the 10b5-1 plan.

Positives

• The exercise of stock options and subsequent sale suggests confidence in the company's valuation, as the CFO chose to exercise the options.
• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating that the transactions were planned and not based on any recent inside information.

Negatives

• The sale of shares by a high-ranking executive could be interpreted negatively by some investors, although it was part of a pre-planned trading strategy.

Risks

• While the sale was pre-planned, significant insider selling can sometimes create negative market sentiment.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. The use of 10b5-1 plans is a common practice to allow insiders to sell shares without being accused of acting on non-public information. This filing is a standard part of corporate governance and transparency.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice across publicly traded companies.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Pfizer also have executives who regularly file Form 4s related to stock options and sales.
• The use of Rule 10b5-1 trading plans is a common strategy among executives in the pharmaceutical industry to manage their stock holdings.

Stakeholder Impact

• The transaction could have a minor impact on shareholder sentiment, depending on how it's perceived.
• Employees holding stock options may be interested in the CFO's actions as a signal of the company's prospects.

Key Dates